As p53 gain-of-function (GOF) mutants have been reported in many cancer types [78,79,80], it could be interesting to investigate if increasing PURPL levels could reduce the p53 levels in cisplatin-resistant ovarian cancer cells. Here, PURPL is linked to ovarian carcinoma.